Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: A 10-year follow-up study of 118 patients

Alessandro Isidori, Francesca Bonifazi, Giuseppe Visani, Filippo Gherlinzoni, Michele Baccarani, Roberto Massimo Lemoli

Research output: Contribution to journalArticle

Abstract

We assessed the impact of unpurged autologous stem cell transplantation (ASCT) on long-term outcome of 118 patients with acute myeloid leukemia (AML) in first complete remission (CR1). With a median follow-up of 95 months, the 10-year overall survival, disease-free survival and relapse risk are, respectively, 54%, 50% and 46%. De novo AML, the presence of a favorable karyotype and intensification of treatment prior to ASCT are independently associated with clinical outcome by multivariate analysis. Thus, a remarkable proportion of AML patients in CR1 can be cured with high-dose therapy and ASCT.

Original languageEnglish
Pages (from-to)139-140
Number of pages2
JournalHaematologica
Volume90
Issue number1
Publication statusPublished - Jan 2005

Keywords

  • AML
  • Autologous stem cell transplantation
  • CR 1
  • Cytogenetics

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Autologous stem cell transplantation for acute myeloid leukemia patients in first complete remission: A 10-year follow-up study of 118 patients'. Together they form a unique fingerprint.

  • Cite this